Pathfinder Cell Therapy's net income is $-1.4M, below the Healthcare sector average of $17B.
Get informed when a big investor buys or sells
+ FollowAs of Sep 2015
Trailing 12 months ending Sep 2015
Loading...
Loading...
Pathfinder Cell Therapy (PFND) currently reports a net income of $-1.4M as of September 2015. That compares with $-1.6M in the prior-year period — up 15.2% year over year. That is below the Healthcare sector average of $17B. Use the charts on this page to explore Pathfinder Cell Therapy's net income history and peer comparisons.
Pathfinder Cell Therapy's net income increased from $-1.6M to $-1.4M — a 15.2% year-over-year increase (period ending September 2015). Watching multi-year history on the chart below helps separate one-off swings from a lasting trend.
Pathfinder Cell Therapy's net income of $-1.4M is lower than the Healthcare sector average of $17B. That is roughly 100.0% below the sector mean. A reading lower peers can reflect different growth expectations, capital structure, or profitability — so it is worth checking the peer comparison chart before drawing conclusions.
Pathfinder Cell Therapy reported $-1.4M in net income as of September 2015. That compares with $-1.6M in the prior-year period — up 15.2% year over year. Absolute dollar amounts are most useful when compared with prior periods, peers, and related line items such as revenue, assets, or liabilities on Stockcircle.
Start with the current net income of $-1.4M, then check the historical chart for trend and the peer comparison chart for relative positioning. The Healthcare average is $17B. From there, open related valuation or income-statement pages for Pathfinder Cell Therapy, and consider following PFND for alerts when major investors trade the stock.